Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc is experiencing a positive outlook due to a successful Phase 3 trial and favorable regulatory conditions, potentially leading to a re-rating and enhanced commercial success probabilities. The company's peak revenue estimate has been increased to $6.8 billion, driven by anticipated strong market uptake of their upcoming vaccine candidate, VAX-31, which could significantly broaden the addressable market for pneumococcal conjugate vaccines. Additionally, impressive Phase 1/2 results, showcasing VAX-31's superiority against common serotypes, are expected to heighten investor interest and contribute to positive clinical outcomes in subsequent trials.

Bears say

Vaxcyte Inc. faces significant downside risks including potential delays in research and development, disappointing clinical results, and lower-than-anticipated commercial uptake of its vaccine candidates. The upcoming readout of the VAX-24 Phase 2 trial is expected to fall short of investor expectations, raising concerns about the company's positioning in a competitive market that is increasingly cautious regarding vaccine approvals. Additionally, the possibility that national vaccine guidelines may not endorse Vaxcyte's products further complicates its commercial viability, emphasizing the inherent instability and unpredictability of the clinical-stage pharmaceutical landscape.

Vaxcyte (PCVX) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Buy based on their latest research and market trends.

According to 4 analysts, Vaxcyte (PCVX) has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.